10 results about "Eubacterium" patented technology

The invention relates to the technical field of microbiology, in particular to application of Eubacterium rectum to preparation of a preparation for relieving rheumatoid arthritis. It is found for the first time that Eubacterium rectum can improve joint inflammation and bone destruction of mice by adjusting immune tolerance, and the Eubacterium rectum is applied to development of microbial preparations containing Eubacterium rectum so as to improve intestinal flora of rheumatoid arthritis patients, so that the effects of adjusting immunity and relieving rheumatoid arthritis conditions are achieved.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

The invention discloses an enteric microbial marker related to type 2 diabetes mellitus, a product and application of the enteric microbial marker, and belongs to the field of biological medicine. The microbial marker is prepared from one or more of streptococcus angularis, giant spheroides angularis, bifidobacterium longum, eubacterium choicense and bifidobacterium bifidum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The invention also provides a product for diagnosing the type 2 diabetes, a prediction system for evaluating the risk that the to-be-detected object is the type 2 diabetes patient, and a computer program product related to the type 2 diabetes. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of type 2 diabetes mellitus, and provides a new tool for clinical diagnosis.

The invention discloses application of Eubacterium rectum in preparation of medicines for treating type 2 diabetes mellitus, and belongs to the technical field of microbial medicines. The strain can promote synthesis of short-chain fatty acid (SCFAs), enhance secretion of glucagon-like peptide-1 (GLP-1) and effectively improve glucose and lipid metabolism disorder and related physiological indexes. Experiments prove that the strain can significantly reduce the fasting blood glucose level, improve the impaired state of glucose tolerance, enhance the insulin secretion ability, regulate abnormal blood lipid metabolism and improve the liver function. The Eubacterium rectum provided by the invention can be widely applied to the development of functional foods, dietary supplements or pharmaceutical preparations, and is suitable for early-stage intervention of diabetes and adjuvant therapy of complications.

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

The application discloses a kind of zürich true bacillus genus specific protein monoclonal antibody TC1 and its application.The monoclonal antibody TC1 includes heavy chain variable region and light chain variable region, and the amino acid sequences of heavy chain variable region and light chain variable region are respectively shown as SEQ ID NO:3 and 4.The antibody conjugated magnetic bead of the application is coupled from the monoclonal antibody TC1 and activated carboxyl magnetic bead.The antibody conjugated magnetic bead of the application can specifically enrich zürich true bacillus genus, and the enrichment efficiency is high, and the enrichment operation is simple, can be applied to the analysis of zürich true bacillus genus metabolite, and can be used for its qualitative and quantitative analysis.

[Problem] The purpose of the present invention is to provide: a composition capable of promoting the secretion of serotonin; food or drink, a cosmetic, and a medicine containing the composition; and methods for producing the same. [Solution] Provided is a serotonin secretion-promoting composition containing at least two types of enteric bacteria. In particular, the enteric bacteria are preferably selected from enteric bacteria belonging to the genus Eubacterium, Clostridium, or Bifidobacterium.

The invention provides an intestinal flora marker for predicting human total lifetime and a construction method of a prediction model of the intestinal flora marker, and belongs to the technical field of biological medicine and precise nutrition. The invention relates to an intestinal flora marker for predicting the total lifetime of human beings. The intestinal flora marker comprises an eubacterium rectum genus (Agathobacter) and / or a butyric acid genus (Butyliccus). The relative abundance of the intestinal flora marker is in significant negative correlation with the death risk, which indicates that the intestinal flora marker may have a protective effect. Meanwhile, survival differences among different risk groups of human total lifetime prediction models constructed on the basis of the intestinal flora markers have statistical significance, which prompts that the models have good survival prediction ability in a training set. The present invention is a precise intervention design for stably predicting individual lifetime in a variety of populations and for prolonging the overall lifetime.

The application discloses a multiple digital PCR detection kit for diagnosing liver cirrhosis intestinal flora disorder. The kit is used for diagnosing pathogens including Soehngenella, Escherichia, Romboutsia, Clostridium, Fusobacterium and Mucispirillum in intestinal flora. By using the kit, specific strains in intestinal microflora in vivo can be detected to diagnose liver cirrhosis, thereby providing a new idea for diagnosis and treatment of liver cirrhosis.

The invention discloses an application of Eubacterium mucilaginosus in preparation of a medicine for preventing and treating a non-alcoholic fatty liver disease. Wherein the preservation number of the Eubacterium mucilaginosus is JCM 6421. In the application, the Eubacterium mucilaginosus can be used for preventing and treating the non-alcoholic fatty liver disease by inhibiting liver fat accumulation, and the Eubacterium mucilaginosus is from healthy people, is a relatively common bacterium genus, is smaller in possibility of adverse reaction and is wider in applicable crowd range.